Home » Stocks » LUMO

Lumos Pharma, Inc. (LUMO)

Stock Price: $21.19 USD -0.94 (-4.25%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 175.81M
Revenue (ttm) 561,000
Net Income (ttm) -12.17M
Shares Out 8.29M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $21.19
Previous Close $22.13
Change ($) -0.94
Change (%) -4.25%
Day's Open 21.94
Day's Range 21.11 - 22.01
Day's Volume 10,182
52-Week Range 0.89 - 35.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 4 weeks ago

Lumos Pharma (LUMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlobeNewsWire - 4 weeks ago

AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumo s Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the com...

GlobeNewsWire - 1 month ago

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the comp...

Seeking Alpha - 2 months ago

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial re...

Zacks Investment Research - 2 months ago

Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the comp...

GlobeNewsWire - 2 months ago

AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...

GlobeNewsWire - 4 months ago

AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the ...

Seeking Alpha - 5 months ago

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

AUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial r...

GlobeNewsWire - 5 months ago

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it ...

GlobeNewsWire - 5 months ago

AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced tha...

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in Lumos Pharma.

About LUMO

Lumos Pharma, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharm... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Richard J. Hawkins
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
LUMO
Full Company Profile

Financial Performance

In 2019, Lumos Pharma's revenue was $936,000, a decrease of -92.50% compared to the previous year's $12.47 million. Losses were -$42.99 million, -19.79% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Lumos Pharma stock is "Buy." The 12-month stock price forecast is 33.00, which is an increase of 55.73% from the latest price.

Price Target
$33.00
(55.73% upside)
Analyst Consensus: Buy